Skip to content
Doctor licensed in Poland · PWZ 3211301 Prescription on the EU model Every day, 5am to 11pm (Irish time)

Mounjaro (tirzepatide): how it works, doses and safety

Mounjaro contains tirzepatide, a medicine injected under the skin once a week. It is licensed for type 2 diabetes and for weight management, in both cases alongside diet and physical activity. This page explains how it works, how the dose is built up, which side effects are reported most often, who needs to be careful and how a prescription can be requested, whether you are starting treatment or continuing it.

What Mounjaro is used for

Mounjaro has two licensed uses, set out in section 4.1 of its SmPC (summary of product characteristics). The first is type 2 diabetes that is not controlled well enough, in adults, adolescents and children aged 10 and over, as an addition to diet and exercise: either on its own when metformin is not suitable or together with other diabetes medicines. The second is weight management, including weight loss and weight maintenance, in adults with obesity or with overweight and at least one weight-related condition, as an addition to a reduced-calorie diet and increased physical activity.

The SmPC states that the safety and efficacy of tirzepatide for weight management have not been established in anyone under 18. More background on the whole group of weight management injections is on our page on weight loss injections.

How tirzepatide works

Tirzepatide is a long-acting agonist at two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both receptors are found in the pancreas, the gut and areas of the brain that regulate appetite. In type 2 diabetes it lowers fasting blood sugar and blood sugar after meals and increases insulin release in a glucose-dependent way.

For weight, the SmPC describes reduced food intake through the regulation of appetite: more feelings of satiety and fullness, less hunger and less intense food cravings. Tirzepatide also delays the emptying of the stomach, which explains several of its side effects and its effect on some tablets taken at the same time.

Pens and strengths in Ireland

Mounjaro holds 12 licences on the HPRA list of authorised medicines, covering both multi-dose KwikPens and single-dose pre-filled pens, with each form licensed in strengths from 2.5 mg through 5 mg, 7.5 mg, 10 mg and 12.5 mg to 15 mg.

The SmPC describes the two pen types. A single-dose pen holds one 0.5 ml dose and has a hidden needle that inserts itself when you press the button. A KwikPen holds four doses of 0.6 ml; needles are not included, and the pen has to be discarded 30 days after first use. Both are stored in a fridge (2 °C to 8 °C) and must not be frozen. A single-dose pen may be kept out of the fridge below 30 °C for up to 21 days in total.

The KwikPen contains 5.4 mg of benzyl alcohol in each dose. If you are pregnant, are breastfeeding or have liver or kidney disease, the package leaflet asks you to speak to your doctor, nurse or pharmacist, because benzyl alcohol can accumulate in the body in large amounts.

Dose and how to use it

Treatment starts at 2.5 mg once a week. After four weeks the dose goes up to 5 mg once a week, and if needed it can be raised in 2.5 mg steps after at least four weeks on the current dose. The recommended maintenance doses for adults are 5 mg, 10 mg and 15 mg, and the maximum is 15 mg once a week. For children and adolescents with type 2 diabetes, the maximum is 10 mg.

StepWeekly dose (SmPC 4.2)
Weeks 1-42.5 mg (starting dose, not a maintenance dose)
From week 55 mg
Further steps, each after at least 4 weeks7.5 mg, 10 mg, 12.5 mg, 15 mg, if needed
Maintenance in adults5 mg, 10 mg or 15 mg; maximum 15 mg

Injecting, missed doses and changing the day

You inject Mounjaro under the skin of the abdomen or thigh; the back of the upper arm is used only if another person gives the injection. It can be given at any time of day, with or without food. Change the injection site with each dose, and if you also inject insulin, use a different site for each. Read the instructions for use in the pack before the first injection.

If you miss a dose, give it as soon as possible within 4 days. If more than 4 days have passed, skip it and inject the next dose on your usual day. You can change your injection day as long as there are at least 3 days between two doses.

Side effects of Mounjaro

The most frequently reported side effects are gastrointestinal, mostly mild or moderate, and more frequent while the dose is being increased. The weight management trials recorded nausea, diarrhoea, vomiting, constipation and abdominal pain as very common, that is, in more than 1 in 10 people. In a weight management trial in people without diabetes, nausea was reported by 24.6% to 33.3% of people on tirzepatide, depending on the dose, against 9.5% on placebo.

Listed in the package leaflet as common, for up to 1 in 10 people, are tiredness, hair loss, dizziness, low blood pressure, indigestion, reflux, bloating, burping, wind, a faster pulse, reactions at the injection site and allergic reactions such as rash or itching. Uncommon side effects (up to 1 in 100) include gallstones, inflammation of the gallbladder, acute pancreatitis and pain at the injection site. Severe allergic reactions are rare.

  • Severe pain in the stomach and back that does not go away can be acute pancreatitis: see a doctor immediately.
  • Difficulty breathing, or swelling of the face, lips or throat, may signal a severe allergic reaction and needs medical help immediately.
  • Vomiting or diarrhoea that stops you keeping fluids down can lead to dehydration and kidney problems: drink enough and seek help if you cannot.
  • If you have diabetes and use insulin or a sulphonylurea, signs of low blood sugar include headache, drowsiness, weakness, dizziness, hunger, confusion, irritability, a fast heartbeat and sweating.

Who should not use Mounjaro, and who needs care

The only contraindication in section 4.3 of the SmPC is hypersensitivity to tirzepatide or to any of the ingredients. Section 4.4 lists situations that need caution. Tirzepatide has not been studied in people with a history of pancreatitis or with severe gastrointestinal disease, including severe gastroparesis. Dehydration from stomach side effects can worsen kidney function, and the SmPC asks for particular attention in older people.

If you have diabetic eye disease (retinopathy), close monitoring is advised, because a rapid improvement in blood sugar can temporarily worsen it. If you use insulin or a sulphonylurea, their dose may need to be lowered. Before an operation under general anaesthesia or deep sedation, tell the team you use tirzepatide: food can stay in the stomach longer, and cases of stomach contents being inhaled into the lungs have been reported with GLP-1 receptor agonists.

Mounjaro and other medicines, including the pill

Tirzepatide delays gastric emptying, so tablets taken alongside it may be absorbed at a different rate, an effect strongest early in treatment. For most oral medicines the SmPC anticipates no change of dose; it does advise monitoring of those with a narrow therapeutic index, warfarin and digoxin among them, particularly when tirzepatide is started and after every dose increase. Paracetamol needs no dose change.

With a combined contraceptive pill, a single 5 mg dose of tirzepatide lowered the peak level of ethinylestradiol by 59% and its total exposure by 20%. The SmPC states that this reduction after a single dose is not considered clinically relevant and that no dose adjustment of oral contraceptives is required. Section 4.6 recommends contraception for women who could become pregnant while using tirzepatide. Contraception during weight management is covered on our page on contraception during weight loss treatment.

Pregnancy and breastfeeding

Tirzepatide is not recommended during pregnancy, or in women who could become pregnant and are not using contraception. If you want to become pregnant, or become pregnant during treatment, it is stopped. Since tirzepatide remains in the body for a long period, the SmPC advises stopping it at least 1 month ahead of a planned pregnancy.

On breastfeeding, the SmPC reports that after a single dose the level in breast milk was undetectable or very low and that tirzepatide could be considered for use during breastfeeding. If you are breastfeeding or plan to, the package leaflet asks you to speak to your doctor before you use it or carry on using it.

Is Mounjaro available without a prescription?

No. On the HPRA list, all 12 Mounjaro licences belong to category A: the medicine needs a prescription that may not be renewed and reaches patients only through pharmacies. In Ireland, the HPRA states, selling prescription medicines online is against the law. Tirzepatide offered for sale online without a prescription does not come through the regulated supply route.

An Irish pharmacist may dispense on a prescription from elsewhere in the EEA if certain conditions are satisfied, among them that the medicine is authorised in Ireland and that it is not a controlled drug. Tirzepatide does not appear in any schedule of the Misuse of Drugs Regulations 2017.

What does it cost?

We do not quote a price for Mounjaro in Ireland, and the medicine is not part of our fee. Our fee covers the doctor's assessment; you pay for the medicine at the pharmacy, at the pharmacy's price. This page's button carries the amount of the assessment fee. What the medicine costs depends on the pen type and strength on your prescription, and the strength changes as the dose is increased. We make no claim about whether a medicine dispensed on this prescription counts towards a medical card or the Drugs Payment Scheme.

Requesting a prescription

Weight Loss Treatment is the route for weight management medicines, whether you are starting treatment or continuing one that another prescriber began. The medical questionnaire covers the medicine you are asking about or a description of your situation, along with your health, other medicines and existing conditions. There is no video call and no telephone consultation. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. The doctor can also request records, test results or a measurement such as your blood pressure, recommend that you are seen in person, or decline the request.

If the doctor issues a prescription, you receive it as a PDF by email. You print the PDF and take the printout to a pharmacy. A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. This is not an Irish ePrescription and it is not sent through Healthmail.

Package leaflet and medical review

For the pen you use, including how to store it and how to inject, refer to the package leaflet in your pack. The European Medicines Agency publishes the full product information, because Mounjaro is authorised centrally for the European Union. Use of tirzepatide is supervised by a doctor; this page is general information and does not replace advice about your own treatment.

Medically reviewed by Damian Wojno, a doctor registered in Poland (licence no. 3211301, Regional Medical Chamber in Olsztyn). He is not on the register of the Irish Medical Council.

Mounjaro in Ireland: do I need a prescription?

Yes. The HPRA list puts every one of the 12 Mounjaro licences in category A: you need a prescription, it cannot be renewed, and only pharmacies supply it. A doctor has to assess whether it is suitable for you before it can be prescribed.

What strengths does Mounjaro come in?

In Ireland, Mounjaro is licensed both as KwikPens that hold four doses and as single-dose pens, in strengths of 2.5 mg, 5 mg and 7.5 mg, and of 10 mg, 12.5 mg or 15 mg. Treatment starts at 2.5 mg once a week, and the maximum is 15 mg once a week.

What are the most common side effects of Mounjaro?

Nausea, diarrhoea, vomiting, constipation and abdominal pain, mostly mild or moderate and more frequent while the dose is being increased. Indigestion, bloating, burping, reflux, dizziness, tiredness and hair loss are also common. Severe stomach pain spreading to the back that does not go away needs a doctor immediately.

Does Mounjaro stop the contraceptive pill working?

The SmPC says no dose adjustment of oral contraceptives is required. A single dose of tirzepatide lowered the peak hormone levels of a combined pill, but the SmPC does not consider this reduction clinically relevant. It recommends contraception for women who could become pregnant while using tirzepatide.

Can I use Mounjaro while breastfeeding?

The SmPC says tirzepatide could be considered for use during breastfeeding, because the level found in breast milk after a single dose was undetectable or very low. If you breastfeed or intend to, check with your doctor first, as the package leaflet asks.

What if I miss a Mounjaro injection?

Inject the missed dose as soon as possible if no more than 4 days have passed. If more than 4 days have passed, skip it and take the next dose on your usual day. Never double the dose to make up for one you forgot, and leave at least 3 days between any two doses.